Business WireJune 23, 2026
FDA Approves the HepQuant SHUNT® Liver Diagnostic Test to Quantify Risk of Large Esophageal Varices in Adult Patients with Compensated Cirrhosis (Child Pugh Class A)
The FDA has granted premarket approval (PMA) for the HepQuant SHUNT® Liver Diagnostic Test to aid in identifying patients unlikely to require EGD.
PRNewswire-PRWeb June 8, 2026
HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence
PRESS RELEASE HepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory Excellence Denver, CO – June 8, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announced that its laboratory has achieved accreditation from the College of American Pathologists (CAP), recognizing…
PRNewswire-PRWeb | May 27, 2026
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO®
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO® PRNewswire-PRWeb DENVER, Colo., May 27, 2026 — HepQuant, LLC announced the presentation of three studies at the 2026 Congress of the European Association for the Study of the Liver (EASL), showcasing the clinical and research value…
PRNewswire-PRWeb | May 5, 2026
2026 DDW Oral Presentation: HepQuant DuO® Disease Severity Index (DSI) Outperforms Child-Pugh and MELD Scores in Predicting Risk of Esophageal Varices
Chicago, IL – May 5, 2026 – HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is excited to announce an oral presentation at Digestive Disease Week (DDW) 2026. Dr. Mitchell Shiffman1 will present data findings and discuss HepQuant DuO® as part of the DDW session:…
PRNewswire-PRWeb January 12, 2026
2026 MASH-TAG Oral Presentation: HepQuant DuO® Reveals Functional and Physiological Heterogeneity to Support Enhanced Clinical Trial Design
“HepQuant DuO is the ideal noninvasive test of liver health with clinical validation data confirming effective characterization of disease severity, tracking of disease progression and treatment impact.”, stated Dr. Gregory T. Everson, Chief Executive Officer of HepQuant. “HepQuant is committed to bringing this important quantitative tool to healthcare providers to transform liver health and improve patient management.”
PRNewswire-PRWebNovember 6, 2025
HepQuant Presents Exciting Abstracts at The Liver Meeting 2025 Demonstrating HepQuant DuO® Utility to Uncover Functional and Physiological Heterogeneity
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, will present three exciting abstracts demonstrating HepQuant DuO utility at The Liver Meeting 2025® conference this week. Each demonstrates how HepQuant DuO test results uncover functional and physiological heterogeneity in patients with advanced MASH and chronic HCV (Child Pugh A5 compared to Child Pugh A6). The third abstract presentation utilizes the HepQuant DuO test to measure the recovery of function in living donors who underwent right lobectomy.
PRNewswire-PRWeb October 14, 2025
HepQuant Announces Exciting New Data Utilizing HepQuant DuO® testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH Cirrhosis
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, announces promising findings from a study utilizing the HepQuant DuO test to evaluate the impact of resmetirom treatment in patients with metabolic dysfunction-associated steatohepatitis (MASH)-related Child-Pugh A cirrhosis. In the peer-reviewed publication, 83% of patients showed either stability or improvement in liver function, as measured by DSI, after 48 weeks.
PRNewswire-PRWebOctober 2, 2025
HepQuant Presents a New Application for the HepQuant DuO™ Test: Improved Study Design and Treatment Monitoring in Clinical Trials
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, presented promising data utilizing the HepQuant DuO™ test to quantify liver function and physiology at an oral presentation on September 30, 2025 during the 9th Annual MASH Drug Development Summit in Boston, MA. Dr. Gregory T. Everson shared exciting data on the use of the HepQuant DuO test as a reasonably likely surrogate endpoint for clinical trials, highlighting this valuable tool in evaluating patients and planning studies.
PRNewswire-PRWebJune 2, 2025
HepQuant Achieves ISO 13485 Certification to Support Scaling of HepQuant DuO™ to Global Clinical Trials
HepQuant, LLC, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is proud to announce ISO 13485 certification as its latest milestone in operational excellence. This internationally recognized certification is a significant achievement that underscores the company's commitment to the highest standards in quality management and regulatory compliance. This milestone enhances HepQuant's abilities to engage in larger, more impactful clinical studies to drive transformative advancements to improve liver health.
May 12, 2025